Rhythm Biotherapeutics Inc. (RBI) is a pre-clinical spinout of the University of Ottawa Heart Institute, founded in November 2022 by Darryl Davis, a cardiac electrophysiologist pioneering novel therapies to prevent and cure atrial fibrillation (AF). The company has developed a patent pending exosome therapy that, in animal studies, has proven to effectively prevent postoperative atrial fibrillation (POAF). RBI’s therapy uniquely addresses atrial inflammation and fibrosis, the fundamental physiological mechanism driving POAF. RBI is currently seeking investors who will accelerate achieving its next milestones. The obtainable market in North America and Europe for POAF therapy is over US$2B per year and growing.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 40 Ruskin Street, Ottawa,ontario K1y 4w7,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.rthm.bio
- HQ
- Ottawa, Ontario
Rhythm Biotherapeutics Inc. Questions
Rhythm Biotherapeutics Inc.'s website is https://www.rthm.bio
Rhythm Biotherapeutics Inc.'s LinkedIn profile is https://ca.linkedin.com/company/rthmbio
Rhythm Biotherapeutics Inc. has
6 employees.
View email and phone details for 6
employees at Rhythm Biotherapeutics Inc..
Rhythm Biotherapeutics Inc.'s industry is
Biotechnology Research
Rhythm Biotherapeutics Inc.'s top competitors are
Virica Biotech,
Capital Bioventures,
Hylid Diagnostics Inc,
Yellowbird Diagnostics, Inc.,
Esphera Synbio Inc,
Cura Therapeutics Inc.,
Biotecanada,
Nuvobio,
Deep Breathe,
Neurenati Therapeutics.
Rhythm Biotherapeutics Inc.'s categories are Biotechnology Research
Rhythm Biotherapeutics Inc.'s founding year is 2022
